Displaying items by tag: department of neurology

Results showed that African American veterans with PTSD had a higher risk of rehospitalization than those without PTSD. However, white veterans with PTSD did not have a significantly higher risk of rehospitalization post-stroke.
These findings could lead to non-invasive, low-cost tests and the early diagnosis of the disease, which progresses for decades before symptoms of dementia emerge.   
New findings from UAB researchers indicates that preventable environmental factors like repeated blows to the head in contact sports and pesticides and herbicides account for a substantial number of Parkinson’s disease cases.  
Most seizures occur in non-medical settings. A UAB epilepsy expert provides information on best practices to help individuals during a seizure.
The task force will develop and disseminate strategies, resources and guidance to better service the Alzheimer’s population.
While preventive treatment with vigabatrin delayed the onset and prevalence of infantile spasms in TSC infants, it had no impact on focal seizures, drug-resistant epilepsy, or improvement of cognitive and behavioral scores at 24 months.
Rachel Smith, Ph.D., professor in the UAB School of Engineering and principal investigator in the Neural Signal Processing and Modeling lab, was recently awarded multiple grants to fund research in seizure onset localization.
TCE is a known environmental risk factor for parkinsonism. UAB researchers will evaluate whether T cell activation caused by TCE exposure leads to cognitive decline.
The National Ataxia Foundation has named UAB a Center of Excellence. The designation is awarded to regional centers providing comprehensive care and services for individuals affected by ataxia and their families.
In a mouse model, border-associated macrophages, not microglia, were essential for the neuroinflammation that precedes neurodegradation. Targeting this subset could be a disease-modifying therapy in neurodegenerative disease.
UAB scientist aims to inspire children from underrepresented backgrounds to pursue a career in science and help them understand that achieving their passions is possible.
UAB was involved in clinical trials that led to an accelerated approval of the drug lecanemab, commercially known as Leqembi, in January 2023. A UAB Alzheimer’s expert discusses the therapy and what full approval means for the AD field.
Page 1 of 13